₹462.35
+₹16.95 (+3.81%)
Closed · As of 26 Aug 3:30 pm
Mkt Cap
₹17,041 Cr
P/E
291.11
ROE
5.05%
ROCE
5.47%
About Cohance Lifesciences Ltd
Cohance Lifesciences is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
Founded
2018
CEO
Vivek Sharma
Employees
2,295
HQ
Hyderabad, India
About Cohance Lifesciences Ltd
Cohance Lifesciences is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
Founded:2018
CEO:Vivek Sharma
Employees:2,295
HQ:Hyderabad, India
Finished Products
1Sale of Products
₹2,079.17Cr2Sale of Services
₹23.20Cr3Other Operating Income
₹17.29Cr4Export Incentives
₹17.27Cr5scrap
₹7.93CrRaw Materials
1Raw Material Consumed
₹473.84Cr2Packing Materials Consumed
₹4.55CrPrice Performance & Market EventsPrice Performance
Loading chart data…
Key Metrics
Trading & valuation snapshot
52W High
₹1,039
52W Low
₹267
Volume1.02M
Avg VolumeN/A
Beta0.84
Dividend Yield0.00%
Key Financial Ratios
Profitability, leverage & efficiency at a glance
P/E Ratio
291.11x
Valuation
P/B Ratio
4.36x
Valuation
EPS
₹1.53
Valuation
Dividend Yield
0.00%
Valuation
ROE
5.05%
Profitability
ROCE
5.47%
Profitability
Revenue by Segment
Contribution & growth by business line
Manufacturing of Bulk Drugs & InterRevenue split N/A
Geographical Revenue Split
Domestic vs international exposure
Domestic
6.4%
International
93.6%
Europe64.7%
USA21.7%
Others7.2%
India6.4%
Strategic Relations
Collaborations, joint ventures & subsidiaries
No collaborations data available.
Forensic Metrics
Financial health & earnings-quality indicators
Revenue Quality
N/A
Days Sales Outstanding
Leverage
0.10x
Debt-to-Equity
Earnings Quality
N/A
Cash Conversion Ratio
Efficiency
N/A
Asset Turnover
Earnings Quality
N/A
Accruals Ratio
Profitability
N/A
Gross Margin
Growth
-3.7%
Sales Growth
These metrics are derived from available financial disclosures and market data. Use them together with company filings and qualitative analysis before making decisions.